918075
NanoFabTx™ PLA-nano
for synthesis of 100 and 200 nm particles
Synonyme(s) :
For nanoparticle synthesis for drug delivery
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12161503
Nomenclature NACRES :
NA.23
Produits recommandés
Description générale
The NanoFabTx™ Polymer drug formulation kit, PLA, for synthesis of 100 and 200 nm particles is a ready-to-use nanoformulation kit for the synthesis of drug-encapsulating PLA-based nanoparticles. This kit provides properly selected PLA based polymers, stabilizer, and protocols for fabrication of PLA nanoparticles by both nanoprecipitation and microfluidic-based synthesis. The microfluidics protocol uses a NanoFabTx™ device kits (911593, sold separately), which provide all the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).Comprehensive protocols for two different particle synthesis methods are included:
- A nanoprecipitation protocol to prepare drug-encapsulated nanoparticles in standard laboratory glassware.
- A microfluidics protocol using commercial platforms or syringe pumps.
Application
The NanoFabTx™ Polymer drug formulation kit, PLA, for synthesis of 100 and 200 nm particles enables users to encapsulate a wide variety of therapeutic drug molecules in PLA-based nanoparticles. Drug encapsulated nanoparticles synthesized with the NanoFabTx™ kits are suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, antigen delivery, and vaccine delivery. Poly(D,L-lactic acid) (PLA) is a biocompatible and biodegradable polymer that has been approved by the FDA for biomedical and pharmaceutical applications. Because of their robust mechanical properties and slow degradation, PLA based nanoparticles have been widely used as drug delivery systems to achieve controlled drug release for different types of therapeutic molecules. This kit minimizes laboratory setup with optimized protocols and step-by-step instruction for synthesizing drug-encapsulated nanoparticle-based formulations. It is designed to help pharmaceutical researches achieve reproducible synthesis with high loading efficiencies without the need for lengthy trial-and-error optimization.
Caractéristiques et avantages
- Ready-to-use nanoformulation kit for PLA nanoparticles
- Step-by-step protocols developed and tested by our formulation scientists
- Flexible synthesis tool to create uniform and reproducible nanoparticles
- Optimized to make nanoparticles 100–200 nm nanoprecipitation or microfluidics with low polydispersity
- Based on non-toxic, biodegradable polymers
Informations légales
NANOFABTX is a trademark of Sigma-Aldrich Co. LLC
Produit(s) apparenté(s)
Réf. du produit
Description
Tarif
Code de la classe de stockage
11 - Combustible Solids
Faites votre choix parmi les versions les plus récentes :
Certificats d'analyse (COA)
Lot/Batch Number
Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.
Si vous avez besoin d'assistance, veuillez contacter Service Clients
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
S Freiberg et al.
International journal of pharmaceutics, 282(1-2), 1-18 (2004-09-01)
Polymer microspheres can be employed to deliver medication in a rate-controlled and sometimes targeted manner. Medication is released from a microsphere by drug leaching from the polymer or by degradation of the polymer matrix. Since the rate of drug release
Robert F Pagels et al.
Journal of controlled release : official journal of the Controlled Release Society, 219, 519-535 (2015-09-12)
Biologically derived therapeutics, or biologics, are the most rapidly growing segment of the pharmaceutical marketplace. However, there are still unmet needs in improving the delivery of biologics. Injectable polymeric nanoparticles and microparticles capable of releasing proteins and peptides over time
C Thomasin et al.
Journal of pharmaceutical sciences, 87(3), 269-275 (1998-04-02)
Phase separation (frequently called coacervation) of poly(lactide) (PLA) and poly(lactide-co-glycolide) (PLGA) is a classical method for drug microencapsulation. Here, attempts have been made to describe this process in the light of thermodynamics. Different PLA/PLGAs were dissolved in either dichloromethane or
Byung Kook Lee et al.
Advanced drug delivery reviews, 107, 176-191 (2016-06-06)
Poly(d,l-lactic acid) (PLA) has been widely used for various biomedical applications for its biodegradable, biocompatible, and nontoxic properties. Various methods, such as emulsion, salting out, and precipitation, have been used to make better PLA micro- and nano-particle formulations. They are
Verónica Lassalle et al.
Macromolecular bioscience, 7(6), 767-783 (2007-06-02)
The controlled release of medicaments remains the most convenient way of drug delivery. Therefore, a wide variety of reports can be found in the open literature dealing with drug delivery systems. In particular, the use of nano- and microparticles devices
Articles
NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.
NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.
NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.
NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique